Thyroid eye disease (TED) typically lasts 18 to 36 months in its active inflammatory phase, though the exact duration varies from person to person. After the inflammation burns out, some eye changes may persist permanently if scarring has occurred. Understanding the phases of the disease helps you anticipate what’s ahead and make informed decisions about treatment timing.
The Active Phase: 6 to 36 Months
TED follows a predictable pattern that doctors call Rundle’s curve, which maps the severity of the disease over time. The disease starts with an active inflammatory phase where symptoms are worsening, hits a peak, then gradually stabilizes. Most sources place the inflammatory phase at 6 to 18 months, though Cleveland Clinic ophthalmologist Dr. Carolyn Hwang tells patients to expect the active phase to last 18 to 36 months. The wide range reflects genuine variability between patients, not just disagreement among experts.
During this active phase, the immune system attacks the tissues behind and around your eyes. The muscles and fat in your eye sockets swell, which pushes the eyes forward (a condition called proptosis), pulls the eyelids open wider than normal, and can restrict eye movement enough to cause double vision. Pain, redness, and a gritty or swollen feeling around the eyes are common. These symptoms tend to worsen over weeks to months before eventually plateauing.
What Happens After Inflammation Stops
Once the active phase ends, TED enters an inactive or fibrotic phase. The inflammation subsides, but the swollen tissues may have developed scar tissue. You’ll know you’ve transitioned when your symptoms stop changing, meaning they’re no longer getting worse, but they may not fully resolve either.
Some changes from the active phase do improve on their own. Eye movement can gradually get better, and eyelid retraction may partially ease. But persistent proptosis, double vision, and eyelid changes are common long-term consequences if significant scarring has occurred. These residual issues are not signs of ongoing disease activity. They’re structural changes left behind by the inflammation, and they’re typically addressed with surgery once the disease has been stable for at least six months.
Smoking Is the Biggest Modifiable Risk Factor
If there’s one thing you can do to shorten and reduce the severity of TED, it’s quitting smoking. A large study of nearly 88,000 adults with Graves’ disease found that current smokers were significantly more likely to need surgery for TED complications. Among current smokers, 3.7% needed orbital decompression surgery compared to 1.9% of people who had never smoked. Strabismus surgery (to correct eye alignment) was performed in 4.6% of current smokers versus 2.2% of never smokers.
Former smokers fared notably better than current smokers, with surgical rates much closer to those who had never smoked. That’s encouraging because it means quitting, even after a TED diagnosis, measurably reduces your risk of a more severe and prolonged course.
How Graves’ Disease Treatment Affects Your Eyes
Since TED is most commonly linked to Graves’ disease, how you treat the underlying thyroid condition matters. Radioactive iodine therapy, a common treatment for Graves’ hyperthyroidism, has been associated with worsening TED, particularly in smokers. Research from the American Thyroid Association found that higher doses of radioactive iodine were more likely to worsen eye symptoms. A calculated, lower-dose approach successfully treated the hyperthyroidism while being less likely to trigger progression of eye disease.
If you have active TED and your endocrinologist is considering radioactive iodine, this is worth discussing. In some cases, doctors will prescribe a short course of steroids alongside the treatment to reduce the risk of an eye flare, or they may recommend an alternative approach to managing your thyroid altogether.
Treatment During the Active Phase
Doctors assess whether TED is active using a scoring system based on signs like pain, redness, swelling, and worsening symptoms. A score of 3 or higher (out of 7 possible points) generally signals that anti-inflammatory treatment is appropriate.
For mild TED, selenium supplementation at 200 micrograms per day has been shown to improve quality of life, reduce eye involvement, and slow disease progression in a well-designed clinical trial. About 90% of surveyed clinicians use this dose for their patients with mild disease.
For moderate to severe active TED, intravenous steroids have long been the standard treatment. A newer option, teprotumumab, received significant attention for its ability to reduce proptosis during the active phase. However, longer-term follow-up has painted a more complicated picture. In one study of 21 consecutive patients treated with teprotumumab, only 33% maintained sustained improvement. Another 38% experienced full reactivation of their disease, with active inflammation returning and eye protrusion worsening back toward pre-treatment levels. Across a larger group of 119 treated patients, 24% required retreatment.
One concern raised by specialists is that teprotumumab may be disease-modulating rather than disease-modifying. In practical terms, this means it temporarily suppresses the disease rather than changing its overall course. Some patients have returned with reactivated TED up to two years after treatment, a time when their doctors expected them to be well past the active phase. There is even concern that the drug could prolong the active window in certain patients by masking inflammation that later returns.
Can TED Come Back After It Resolves?
True recurrence of TED after the disease has fully entered its inactive phase is uncommon but possible. The reactivation cases seen with teprotumumab appear to be distinct from natural recurrence, representing patients whose disease was suppressed rather than resolved. In the natural course of untreated or conventionally treated TED, most patients move through the active phase once and then stabilize permanently.
That said, keeping your thyroid levels well controlled reduces the risk of reactivation. Both hyperthyroidism and hypothyroidism can aggravate TED, so consistent monitoring and medication adjustments are important even after your eyes have stabilized. The goal is steady, normal thyroid hormone levels maintained over time rather than levels that swing between high and low.
A Realistic Timeline to Plan Around
If you’ve recently been diagnosed, here’s roughly what to expect. The first 6 to 12 months tend to be when symptoms are worsening most actively. Somewhere between 12 and 24 months, most people hit the plateau where things stop getting worse. By 24 to 36 months, the disease is typically in its stable phase. After at least 6 months of confirmed stability, reconstructive surgery can be considered for any lasting changes like persistent bulging eyes, eyelid retraction, or double vision.
The total journey from diagnosis to final surgical rehabilitation, if surgery is needed, often spans 2 to 4 years. Not everyone needs surgery. Mild cases, especially those treated early with selenium and thyroid control, may resolve with minimal lasting effects. Severe cases with compressive optic neuropathy (where swollen tissues press on the nerve that carries vision) require urgent intervention regardless of where you are in the disease timeline.